Ipsen promotes new CMO from within
pharmafile | January 31, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | biotech, drugs, ipsen, pharma, pharmaceutical
Ipsen has announced that Sotirios G. Stergiopoulos will become its newest Chief Medical Officer, performing the role alongside his current position as SVP, Head of Global Medical Affairs. The promotion represents a rapid rise for Stergiopoulos, having only joined the company in January 2017.
He will report to Alexandre Lebeaut, Executive Vice-President R&D and Chief Scientific Officer, who revealed part of the reason behind the promotion: “Sotirios has extensive experience in directing global medical affairs strategies and a strong expertise in oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumour indications. We are delighted to appoint him to an expanded role through which he will make the voice of the patient heard at the highest levels of the organization and represent the company externally as its primary medical representative.”
The experience that Lebeaut mentions comes after Stergiopoulos moved through various positions across the pharma and biotech space before joining Ipsen. He has experience working within oncology at Bayer, holding a similar position at Novartis before moving onto work at Celgene and Shire.
Stergiopoulos commented on the promotion: “I am delighted to take on this leading role at Ipsen. This is an exciting time for Ipsen with significant growth and evolution. Together with our experienced leadership team, I look forward to helping our company continue to bring innovative new medicines to our patients.”
Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the …
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …